Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/14/2025 | $56.00 | Hold → Buy | TD Cowen |
3/19/2025 | Outperform → Perform | Oppenheimer | |
1/3/2025 | $60.00 | Peer Perform → Outperform | Wolfe Research |
9/12/2024 | $42.00 | Equal Weight | Wells Fargo |
8/27/2024 | $55.00 | Buy | Redburn Atlantic |
8/6/2024 | $46.00 → $44.00 | Overweight → Neutral | JP Morgan |
1/19/2024 | $40.00 → $41.00 | Buy → Neutral | Citigroup |
1/4/2024 | $42.00 | Market Perform | TD Cowen |
8-K - Carlyle Group Inc. (0001527166) (Filer)
SCHEDULE 13G/A - Carlyle Group Inc. (0001527166) (Subject)
13F-HR - Carlyle Group Inc. (0001527166) (Filer)
TD Cowen upgraded Carlyle Group from Hold to Buy and set a new price target of $56.00
Oppenheimer downgraded Carlyle Group from Outperform to Perform
Wolfe Research upgraded Carlyle Group from Peer Perform to Outperform and set a new price target of $60.00
BIRMINGHAM, Ala. and NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Diversified Energy Company PLC ((LSE: DEC, NYSE:DEC) ("Diversified," or "DEC"), a leading publicly traded natural gas and liquids production company, and global investment firm Carlyle (NASDAQ:CG) have today announced a strategic partnership to invest in up to $2 billion in existing proved developed producing (PDP) natural gas and oil assets across the United States. This exclusive partnership will combine Carlyle's deep credit and structuring expertise, led by Carlyle's asset-backed finance (ABF) team, with Diversified's market-leading operating capabilities and differentiated business model of acquiring and optimizing port
Transaction positions company for accelerated growth through improved capital structure and simplified governance LINDON, Utah and NEW YORK, June 4, 2025 /PRNewswire/ -- Trucordia today announced it will receive a $1.3 billion strategic investment from global investment firm Carlyle's Global Credit platform. The transaction will reduce Trucordia's leverage and simplify its governance structure by repurchasing units from existing minority investors. The transaction, which is expected to close this month and values Trucordia at $5.7 billion, provides the company with long-term
New management, led by David Meek, is committed to rapidly scaling access to lifechanging gene therapies Significant capital commitment from Carlyle and SK Capital will enable bluebird to grow and accelerate patient access bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers bluebird bio (NASDAQ:BLUE) ("bluebird"), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capital Partners, LP ("SK Capital"). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer